The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxic T lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca).
Carlos Almeida Ramos
No relevant relationships to disclose
Neeharika Narala
No relevant relationships to disclose
Ann M. Leen
No relevant relationships to disclose
Ulrike Gerdemann
No relevant relationships to disclose
Erich M. Sturgis
No relevant relationships to disclose
Matthew L. Anderson
No relevant relationships to disclose
Barbara Savoldo
No relevant relationships to disclose
Helen E. Heslop
No relevant relationships to disclose
Malcolm K. Brenner
No relevant relationships to disclose
Cliona M. Rooney
No relevant relationships to disclose